Published in World J Gastroenterol on August 14, 2006
Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol (2013) 1.83
Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. Clin Gastroenterol Hepatol (2012) 1.74
Sleep duration affects risk for ulcerative colitis: a prospective cohort study. Clin Gastroenterol Hepatol (2014) 1.70
Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol (2011) 1.65
Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res (2016) 1.47
Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med (2012) 1.44
Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol (2009) 1.37
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest (2007) 1.32
Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp (2012) 1.28
Inflammatory bowel disease: pathogenesis. World J Gastroenterol (2014) 1.26
Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol (2011) 1.26
Environmental triggers for inflammatory bowel disease. Curr Gastroenterol Rep (2013) 1.26
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 1.00
Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis (2010) 0.99
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A (2013) 0.97
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol (2014) 0.96
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. J Immunol (2009) 0.91
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol (2010) 0.91
Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis (2011) 0.90
Oral pathology in inflammatory bowel disease. World J Gastroenterol (2016) 0.86
Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One (2014) 0.85
Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther (2016) 0.84
Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open (2015) 0.84
Multicenter case-control study of the risk factors for ulcerative colitis in China. World J Gastroenterol (2013) 0.83
Serological markers of inflammatory bowel disease. Biochem Med (Zagreb) (2013) 0.83
Poly-γ-glutamic acid attenuates angiogenesis and inflammation in experimental colitis. Mediators Inflamm (2013) 0.83
Inflammatory bowel disease serology in Asia and the West. World J Gastroenterol (2013) 0.83
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model. Dig Dis Sci (2011) 0.81
Effect of glucans from Caripia montagnei mushroom on TNBS-induced colitis. Int J Mol Sci (2014) 0.81
Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol (2015) 0.81
Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol (2008) 0.80
Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. J Biomed Biotechnol (2012) 0.80
Erythrocyte deformability and oxidative stress in inflammatory bowel disease. Dig Dis Sci (2011) 0.80
No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn's disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol (2007) 0.79
Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels. Clin Exp Immunol (2010) 0.79
High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.79
Nutritional therapy for active Crohn's disease. World J Gastroenterol (2008) 0.78
Dietary supplementation of arachidonic acid increases arachidonic acid and lipoxin A₄ contents in colon, but does not affect severity or prostaglandin E₂ content in murine colitis model. Lipids Health Dis (2014) 0.78
Haplotype analyses of DNA repair gene polymorphisms and their role in ulcerative colitis. PLoS One (2014) 0.78
Identification of Environmental Factors Associated with Inflammatory Bowel Disease in a Southwestern Highland Region of China: A Nested Case-Control Study. PLoS One (2016) 0.77
Butyrate enhancement of inteleukin-1β production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells. J Clin Biochem Nutr (2011) 0.77
Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol (2012) 0.77
Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats. Mol Med Rep (2016) 0.76
High incidence of inflammatory bowel disease with improved hygiene and failure to get human-like IBD in laboratory animals. World J Gastroenterol (2007) 0.76
Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y) (2014) 0.75
Increased wall thickness using ultrasonography is associated with inflammation in an animal model of experimental colitis. Clin Exp Gastroenterol (2012) 0.75
Ulcerative Colitis and Its Association with Salmonella Species. Interdiscip Perspect Infect Dis (2016) 0.75
Gastrointestinal Infections in Deployed Forces in the Middle East Theater: An Historical 60 Year Perspective. Am J Trop Med Hyg (2015) 0.75
p38α regulates actin cytoskeleton and cytokinesis in hepatocytes during development and aging. PLoS One (2017) 0.75
Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis. World J Gastroenterol (2008) 0.75
Diet, Gut Microbiome and Epigenetics: Emerging Links with Inflammatory Bowel Diseases and Prospects for Management and Prevention. Nutrients (2017) 0.75
Patchouli oil ameliorates acute colitis: A targeted metabolite analysis of 2,4,6-trinitrobenzenesulfonic acid-induced rats. Exp Ther Med (2017) 0.75
Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. World J Gastroenterol (2017) 0.75
NF-kappa B activation correlates with disease phenotype in Crohn's disease. PLoS One (2017) 0.75
Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis. Intest Res (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med (2002) 9.26
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol (2004) 8.45
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 5.65
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med (1994) 5.46
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 4.40
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) (1982) 4.08
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci (1984) 3.76
Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology (2005) 3.41
Changing patterns of infectious disease. Nature (2000) 3.21
Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol (1983) 3.21
Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology (1997) 3.00
Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet (2005) 2.93
Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut (2000) 2.79
Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 2.78
IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol (1999) 2.58
Smoking habits and recurrence in Crohn's disease. Gastroenterology (1994) 2.30
Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol (2005) 2.26
Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology (2005) 2.25
Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet (2004) 2.23
Platelets: signaling cells in the immune continuum. Trends Immunol (2004) 2.18
Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol (1999) 2.11
The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 2.02
Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med (1987) 2.02
Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest (1985) 1.99
Crohn's disease after in-utero measles virus exposure. Lancet (1996) 1.98
Alterations of IgM, IgG, and IgA Synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology (1981) 1.98
Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology (1999) 1.88
The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut (2003) 1.84
Evidence of persistent measles virus infection in Crohn's disease. J Med Virol (1993) 1.76
Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev (2004) 1.61
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut (2003) 1.56
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology (1997) 1.51
Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology (1998) 1.48
Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol (1986) 1.46
Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology (2003) 1.44
Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol (2000) 1.43
Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol (2005) 1.43
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology (1999) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest (1990) 1.35
Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology (1986) 1.31
Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology (1992) 1.27
Immunoregulation in the gut: success and failures in human disease. Gut (2002) 1.25
Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol (2003) 1.22
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol (2004) 1.14
Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol (2005) 1.12
Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet (1998) 1.06
Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut (2004) 1.04
Inflammatory bowel disease and smoking--a review. Am J Gastroenterol (1998) 0.97
Hope for the hygiene hypothesis: when the dirt hits the fan. J Asthma (2005) 0.94
Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut (1998) 0.92
Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med (2000) 0.92
Ulcerative colitis. N Engl J Med (2011) 6.14
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology (2003) 2.53
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol (2007) 1.64
Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev (2004) 1.61
The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol (2005) 1.55
Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol (2009) 1.51
Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol (2004) 1.51
Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.49
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology (2003) 1.42
Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology (2006) 1.41
Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis (2007) 1.30
Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol (2009) 1.27
Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis. J Pharmacol Exp Ther (2004) 1.27
Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut (2006) 1.26
Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol (2006) 1.23
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol (2004) 1.17
Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol (2004) 1.17
Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis (2010) 1.12
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol (2005) 1.04
Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol (2004) 1.04
Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2011) 1.03
An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol (2005) 1.03
Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci (2008) 1.02
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety? N Engl J Med (2004) 1.02
Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology (2010) 0.97
Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis (2002) 0.97
Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis (2008) 0.96
Redox equilibrium in mucosal T cells tunes the intestinal TCR signaling threshold. J Immunol (2005) 0.95
Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.95
Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest (2002) 0.93
Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther (2006) 0.93
Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis. Am J Physiol Gastrointest Liver Physiol (2006) 0.92
HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.92
Critical role of caspases in the regulation of apoptosis and proliferation of mucosal T cells. Gastroenterology (2002) 0.92
Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis (2014) 0.91
Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol (2008) 0.91
Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology (2005) 0.90
Pathogenesis of postoperative recurrence in Crohn's disease. Gut (2010) 0.90
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology (2006) 0.90
In vitro model of acute esophagitis in the cat. Am J Physiol Gastrointest Liver Physiol (2005) 0.89
Hydrogen peroxide contributes to motor dysfunction in ulcerative colitis. Am J Physiol Gastrointest Liver Physiol (2003) 0.89
HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol (2010) 0.88
Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J Physiol Cell Physiol (2005) 0.88
Inflammatory bowel disease. Best Pract Res Clin Gastroenterol (2002) 0.87
Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86
Intestinal fibroblast-derived IL-10 increases survival of mucosal T cells by inhibiting growth factor deprivation- and Fas-mediated apoptosis. J Immunol (2005) 0.85
Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis (2013) 0.85
Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm Bowel Dis (2003) 0.85
Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets (2008) 0.84
Progress in basic inflammatory bowel disease research. Semin Pediatr Surg (2007) 0.82
Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology (2012) 0.81
Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am J Gastroenterol (2009) 0.81
News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010. J Crohns Colitis (2010) 0.80
Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J Immunol (2004) 0.80
Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized? Dig Dis (2015) 0.79
The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol Gastrointest Liver Physiol (2009) 0.79
Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.79
Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet (2013) 0.79
Inflammatory bowel disease: evolutionary concepts in biology, epidemiology, mechanisms and therapy. Curr Opin Gastroenterol (2013) 0.79
IBD: advances in pathogenesis, complications, diagnosis, and therapy. Curr Opin Gastroenterol (2012) 0.78
A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease. Inflamm Bowel Dis (2013) 0.78
Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol (2005) 0.78
Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology (2012) 0.78
Probiotics in inflammatory bowel disease: yet another mechanism of action? Gastroenterology (2006) 0.77
Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients. Am J Physiol Gastrointest Liver Physiol (2004) 0.77
Early and late inflammatory bowel disease: why and how are they different? Curr Opin Gastroenterol (2011) 0.77
Targeting the innate immune system in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol (2011) 0.76
Inflammatory bowel disease: new insights into mechanisms of inflammation and increasingly customized approaches to diagnosis and therapy. Curr Opin Gastroenterol (2004) 0.76
Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis (2007) 0.76
Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation (2003) 0.76
Eosinophilic esophagitis: new insights into an emerging disease. Gastroenterology (2006) 0.75
Current perspectives in inflammatory bowel disease: stress response and autophagy, host-microbe mutualism, immune duality and plasticity, and early versus late disease. Curr Opin Gastroenterol (2010) 0.75
First international summit on fibrosis in intestinal inflammation: mechanisms and biological therapies. Fibrogenesis Tissue Repair (2010) 0.75
Non-stop progress in inflammatory bowel disease: new players, new understanding, new therapies. Curr Opin Gastroenterol (2006) 0.75
Inflammatory bowel disease: genetics and much more. Curr Opin Gastroenterol (2002) 0.75
More answers and more questions in inflammatory bowel disease. Curr Opin Gastroenterol (2003) 0.75
Endothelial Cell-Immune Cell Interaction in IBD. Dig Dis (2016) 0.75